UnknownPHASE2, PHASE3NCT04228393

The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Wei Zhao
Principal Investigator
Wei Zhao, Ph.D
Shandong University
Intervention
6-mercaptopurine(drug)
Enrollment
82 enrolled
Eligibility
1-18 years · All sexes
Timeline
20202022

Study locations (1)

Collaborators

Institute of Hematology & Blood Diseases Hospital, China · Qianfoshan Hospital · Qilu Hospital of Shandong University · Children's Hospital of Hebei Province · The Affiliated Hospital of Qingdao University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04228393 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials